Share on StockTwits
 

BTG (LON:BTG)‘s stock had its “overweight” rating reaffirmed by research analysts at JPMorgan Chase & Co. in a report released on Tuesday, AmericanBankingNews.com reports. They currently have a GBX 630 ($10.38) target price on the stock. JPMorgan Chase & Co.’s target price suggests a potential upside of 4.05% from the stock’s previous close.

Shares of BTG (LON:BTG) traded up 2.28% on Tuesday, hitting GBX 605.50. The stock had a trading volume of 512,493 shares. BTG has a 52-week low of GBX 316.20 and a 52-week high of GBX 624.00. The stock has a 50-day moving average of GBX 583.3 and a 200-day moving average of GBX 453.6.

A number of other firms have also recently commented on BTG. Analysts at Deutsche Bank raised their price target on shares of BTG from GBX 610 ($10.05) to GBX 635 ($10.46) in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at N+1 Singer reiterated a “sell” rating on shares of BTG in a research note to investors on Thursday, January 2nd. They now have a GBX 490 ($8.07) price target on the stock. Finally, analysts at N+1 Singer initiated coverage on shares of BTG in a research note to investors on Thursday, December 19th. They set a “sell” rating and a GBX 490 ($8.07) price target on the stock. Three research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of GBX 547.25 ($9.02).

BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.